Clinical Trial Update: A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Gimistotug (BGB-A445) in combination with other investigational agents for non-small cell lung cancer has completed, and trial results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gimistotug (BGB-A445)

Snippet

Sponsor: BeiGene | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-01-05